Combination of Sumatriptan and Naproxen for Migraine—Reply
-
jbrandes@nashvilleneuroscience.com
Nashville Neuroscience Group
Nashville, Tennessee
- David Kudrow, MD
-
California Medical Clinic for Headache
Santa Monica
- Stuart R. Stark, MD
-
The Innovative Clinical Research Center
Alexandria, Virginia
-
Headache Institute
Newport Beach, California
- James U. Adelman, MD
-
Headache Wellness Center
Greensboro, North Carolina
-
OrthoNeuro
Columbus, Ohio
- W. James Alexander, MD, MPH;
- Susan E. Spruill, MS
-
POZEN Inc
Chapel Hill, North Carolina
- Pamela S. Barrett, PharmD;
- Shelly E. Lener, PharmD
-
GlaxoSmithKline
Research Triangle Park, North Carolina
Since this article does not have an abstract, we have provided the first 150 words of the full text.
In Reply: Drs Hill and Hope indicate an apparent preference for coadministration of the separate components of sumatriptan–naproxen sodium for migraine attacks. We believe that our study provides evidence of efficacy and safety of the single fixed-dose table in replicated randomized controlled trials, whereas trials of coadministration of specific regimens of the individual components have not been replicated.
The practicalities of treatment remain at issue with migraine. Adherence to prescribing directions is often difficult during an acute migraine attack—hence, our concerns of relapse to a “step care” situation—and failure of adherence is unlikely to provide patients with the degree of efficacy reported in our study.1 The prescribing simplicity of a single sumatriptan–naproxen sodium tablet should help improve adherence.
Financial Disclosures: Dr Brandes reports having received clinical research or educational support from Merck, GlaxoSmithKline, UCB Pharma, Allergan, Johnson & Johnson, AstraZeneca, Pfizer, Bristol-Myers Squibb, Winston Laboratories, Sanofi-Aventis, Elan Pharmaceuticals, Novartis, …
